Efficiency of platinum-based chemotherapy re-induction for adrenocortical cancer treatment
DOI: 10.54647/cm32932 85 Downloads 4314 Views
Author(s)
Abstract
The combination of platinum-based chemotherapy with mitotane (m) is the standard first-line therapy for metastatic adrenocortical cancer (ACC) with long-term disease control in approximately 25% of patients. Considering the lack of effective regimens for second and subsequent lines of therapy, it seems relevant to evaluate the effectiveness of platinum-based chemotherapy re-induction for patients with long platinum-free interval. Aim:Evaluation of the platinum-based chemotherapy re-induction efficiency with or without mitotane for patients with metastatic ACC.Materials and methods:This retrospective clinical study included patients with disease progression ≥ 6 months after completion of platinum-based chemotherapy for metastatic ACC. Results:17 patients were included, of which 16 received EDP+/-m regimen and 1 - EP. The median platinum-free interval was 8.3 months (7.2-39.7). Concurrent mitotane therapy was administered in 14 patients (82.35%), all of them achieved therapeutic concentration. Objective response and disease control ≥6 months rate were observed in 23.52% (N=4) and 52.94% (N=9), respectively. The median progression-free survival was 6.17 months, and the median overall survival 15.63 months.Conclusion:This study demonstrated the efficacy of platinum-based chemotherapy re-induction in metastatic ACC. The selected group of patients in our study with relatively platinum-sensitive disease does not allow to perform cross trial comparisons. Based on the results described above, we recommend considering re-induction of platinum-based chemotherapy with mitotane for patients with a platinum-free interval of ≥6 months as an option of second or further lines of treatment.
Keywords
adrenocortical cancer, re-induction, platinum-based chemotherapy, EDP, mitotane
Cite this paper
Zhulikov Ya., Kovalenko E., Bokhian V., Evdokimova E., Khoroshilov M., Gabrava M., Kolobanova E., Artamonova E.,
Efficiency of platinum-based chemotherapy re-induction for adrenocortical cancer treatment
, SCIREA Journal of Clinical Medicine.
Volume 7, Issue 5, October 2022 | PP. 302-311.
10.54647/cm32932
References
[ 1 ] | Schteingart DE, Doherty GM, Gauger PG et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 2005 Sep;12(3):667-80. doi: 10.1677/erc.1.01029. PMID: 16172199. |
[ 2 ] | Polat B, Fassnacht M, Pfreundner L, Guckenberger M et al. Radiotherapy in adrenocortical carcinoma. Cancer. 2009 Jul 1;115(13):2816-23. doi: 10.1002/cncr.24331. PMID: 19402169. |
[ 3 ] | Fassnacht M, Terzolo M, Allolio B et al. FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012 Jun 7;366(23):2189-97. doi: 10.1056/NEJMoa1200966. Epub 2012 May 2. PMID: 22551107. |
[ 4 ] | Urup, T., Pawlak, W. Z., Petersen, P. M. et al. Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study. British journal of cancer, 108(10), 1994–1997. https://doi.org/10.1038/bjc.2013.229 |
[ 5 ] | Sperone P, Ferrero A, Daffara F, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010;17(2):445-453. |
[ 6 ] | Henning JEK, Deutschbein T, Altieri B, et al. Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. J Clin Endocrinol Metab. 2017;102(11):4323-4332. |
[ 7 ] | Zhulikov Y.A., Kovalenko E.I., Bohyan V.Yu. et al. Efficacy of EDP ± mitotane chemotherapy in the treatment of metastatic adrenocortical carcinoma. Predictive and prognostic factors of efficacy. Malignant tumours. 2021;11(1):37-46. |
[ 8 ] | Parianos C, Kyriakopoulos G, Kostakis ID et al. Adrenocortical Cancer: A 20-Year Experience of a Single Referral Center in Prognosis and Outcomes. Horm Metab Res. 2021 Nov;53(11):709-716. doi: 10.1055/a-1666-9026. Epub 2021 Nov 5. PMID: 34740271. |